Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Mar 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain inherited immune system defects might lead to the development of lymphomas, which are types of cancer that affect the lymphatic system, particularly in children. The researchers aim to find out if these immune system issues, known as Inborn Errors of Immunity (IEI), can be identified in kids who have been diagnosed with Hodgkin's or non-Hodgkin's lymphoma. By understanding the underlying immune problems, doctors can provide more targeted treatments, rather than just standard chemotherapy, which may be more effective for these patients.

To participate in this study, patients must have a diagnosis of Hodgkin's lymphoma or non-Hodgkin's lymphoma and may show signs of immune system issues, such as unusual infections or a family history of immune problems. The trial is open to children and young adults of all ages. Participants will undergo a variety of tests to examine their immune system and genetic makeup, which will help the researchers learn more about the connection between immune defects and lymphoma. This research could lead to better treatment options and improved outcomes for children facing these challenging health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a clinical diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL) with or without signs of immune dysregulation (lymphoproliferation, autoimmunity, hypogammaglobulinaemia, family history of immunodeficiency).
• • Patients with previous HL or NEIL lymphoma who have developed, concomitantly with the tumour or subsequently, clinical manifestations mentioned above attributable to a congenital defect of immunity.
• Exclusion Criteria:
• • Patients with known genetic diseases, or who do not consent to participate in the study